Analysts See $-0.16 EPS for VolitionRx Limited (VNRX); ENQUEST PLC LONDON ORDINARY SHARES UNIT (ENQUF) Shorts Increased By 29.79%

April 17, 2018 - By Adrian Mccoy

VolitionRx Limited (NYSEAMERICAN:VNRX) Logo

Analysts expect VolitionRx Limited (NYSEAMERICAN:VNRX) to report $-0.16 EPS on May, 10.They anticipate $0.03 EPS change or 23.08% from last quarter’s $-0.13 EPS. After having $-0.15 EPS previously, VolitionRx Limited’s analysts see 6.67% EPS growth. The stock decreased 1.94% or $0.0429 during the last trading session, reaching $2.1671. About 38,992 shares traded. VolitionRx Limited (NYSEAMERICAN:VNRX) has declined 42.82% since April 17, 2017 and is downtrending. It has underperformed by 54.37% the S&P500.

ENQUEST PLC LONDON ORDINARY SHARES UNIT (OTCMKTS:ENQUF) had an increase of 29.79% in short interest. ENQUF’s SI was 1.18M shares in April as released by FINRA. Its up 29.79% from 908,000 shares previously. With 100 avg volume, 11785 days are for ENQUEST PLC LONDON ORDINARY SHARES UNIT (OTCMKTS:ENQUF)’s short sellers to cover ENQUF’s short positions. The SI to ENQUEST PLC LONDON ORDINARY SHARES UNIT’s float is 0.13%. It closed at $0.44 lastly. It is down 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

EnQuest PLC, an oil and gas development and production company, together with its subsidiaries, explores for, extracts, and produces hydrocarbons in the United Kingdom Continental Shelf and Malaysia. The company has market cap of $522.43 million. The firm operates through North Sea and Malaysia divisions. It currently has negative earnings. It primarily holds interests in the Thistle/Deveron, Heather/Broom, the Dons area, Magnus, the Greater Kittiwake Area, Scolty/Crathes, and Alma/Galia; and in the Kraken development, and a non-operated interest in the Alba producing oil field, as well as the PM8/Seligi production sharing contract and the Tanjong Baram risk services contract in Malaysia.

Investors sentiment decreased to 1.2 in 2017 Q4. Its down 5.80, from 7 in 2017Q3. It worsened, as 3 investors sold VolitionRx Limited shares while 2 reduced holdings. 2 funds opened positions while 4 raised stakes. 4.52 million shares or 51.36% less from 9.30 million shares in 2017Q3 were reported. Knoll Mngmt L P holds 0.91% or 351,538 shares in its portfolio. Northern Trust Corp reported 22,714 shares. Creative Planning holds 0% or 13,200 shares. Blackrock reported 11,219 shares stake. Bridgeway Capital Mgmt owns 109,400 shares or 0% of their US portfolio. Morgan Stanley holds 63,400 shares. Lagoda Management L P has invested 3.94% in VolitionRx Limited (NYSEAMERICAN:VNRX). Geode Mgmt Ltd Liability Corp has invested 0% in VolitionRx Limited (NYSEAMERICAN:VNRX). Royal Fincl Bank Of Canada holds 0% or 14,007 shares. Bessemer Gp invested in 10,000 shares. Leisure Capital Mngmt, a California-based fund reported 74,863 shares. Garrison Bradford And Associates Inc reported 0.04% stake. Brown Brothers Harriman And holds 3,823 shares. Vanguard Grp Inc holds 204,994 shares. 10,335 are owned by Financial Bank Of Ny Mellon Corp.

VolitionRx Limited, a life sciences company, focuses on developing blood tests to diagnose a range of cancers. The company has market cap of $65.06 million. The firm is involved in the development of epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. It currently has negative earnings. It develops blood assays in the Nu.Q-X family to detect nucleosomes containing specific nucleotides; and blood assays in the Nu.Q-V family to detect nucleosomes containing specific histone variants.

VolitionRx Limited (NYSEAMERICAN:VNRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>